• Orion initiated a Phase 1 trial of bispecific antibody ODM-216, its first biologic clinical development asset, in the third quarter of 2026.
• Interim DASL-HiCaP Phase 3 results presented at ESMO 2026 indicated darolutamide could offer a treatment option in an earlier prostate cancer setting.
• Research and development spending rose 20.3% to EUR 168.2 million in January-September.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orion Oyj published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280600OMX_____CNEWS_EN_GNW1001280316_en) on October 28, 2026, and is solely responsible for the information contained therein.